title: A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
abstract: Recent studies have indicated that the development of cyclin-dependent kinase (cdk)2 inhibitors that deregulate E2F are a plausible pharmacological strategy for novel antineoplastic agents. We show here that 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516), a novel 3-substituted indolinone compound, binds to and selectively inhibits the activity of cdk2. This inhibition results in a time-dependent decrease (4-64%) in the phosphorylation of the retinoblastoma protein pRb, an increase in caspase-3 activation (5-84%), and alterations in cell cycle resulting in either a G(0)-G(1) or a G(2)-M block. We also report here cell line differences in the cdk-dependent phosphorylation of pRb. These findings demonstrate that SU9516 is a selective cdk2 inhibitor and support the theory that compounds that inhibit cdk2 are viable resources in the development of new antineoplastic agents.
authors.affiliation: Division of Oncology, Department of Medicine, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York 10461, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Lane
authors.forename: B
authors.initials: B
authors.lastname: Yu
authors.forename: A
authors.initials: A
authors.lastname: Rice
authors.forename: K E
authors.initials: KE
authors.lastname: Lipson
authors.forename: C
authors.initials: C
authors.lastname: Liang
authors.forename: L
authors.initials: L
authors.lastname: Sun
authors.forename: C
authors.initials: C
authors.lastname: Tang
authors.forename: G
authors.initials: G
authors.lastname: McMahon
authors.forename: R G
authors.initials: RG
authors.lastname: Pestell
authors.forename: S
authors.initials: S
authors.lastname: Wadler
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects*; D042846:CDC2-CDC28 Kinases; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D008968:Molecular Conformation; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D016160:Retinoblastoma Protein / Q000378:metabolism; D013379:Substrate Specificity; D014407:Tumor Cells, Cultured
chemical_list: D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D007093:Imidazoles; D007211:Indoles; D016160:Retinoblastoma Protein; C433985:SU 9516; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases